It was thus envisioned that the anti-cancer effects of metformin could be due to its ability to reduce circulating levels of glucose and consequently of insulin and insulin-like growth factor 1(IGF-1) that are suspected to feed different cancers expressing the receptors for these growth factors on their surface (23–26). The gene discussed is IGF1; the disease is cancer.